Loading stock data…
IMCR
$28.16+0.25 (+0.90%)
Market ClosedLast close May 1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunocore Holdings plc in the Healthcare sector is trading at $28.16. The stock is currently near its 52-week low of $27.44, remaining 15.9% below its 200-day moving average. Technical signals show oversold RSI of 22 and bearish MACD signal, explaining why IMCR maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 22) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.16
Potential Upside
5%
Whystock Fair Value$29.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$63.86+126.8%
Range$33.00 – $100.00
Fundamentals
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internatio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.52B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.33%
Volume
Today's trading volume
507,381
Recent News
Immunocore Details KIMMTRAK Growth, TCR Platform and Key Readouts at Needham Conference
Immunocore (NASDAQ:IMCR) executives highlighted the company’s T-cell receptor (TCR) platform, commercial momentum for KIMMTRAK, and several upcoming clinical milestones during a presentation at the Needham Healthcare Conference. Platform focus: soluble TCRs and intracellular targets Management desc
A Look At Immunocore (IMCR) Valuation After Jefferies Downgrade And Kimmtrak Growth Concerns
Jefferies downgrade puts Immunocore in focus Immunocore Holdings (IMCR) came under renewed scrutiny after Jefferies cut its rating to Hold on March 16, 2026, citing concerns about Kimmtrak approaching peak sales and uncertainty around the broader pipeline. See our latest analysis for Immunocore Holdings. The downgrade has landed after a weak run for the shares, with a 30 day share price return of 8.46% and a 90 day share price return of 18.52% decline. The 1 year total shareholder return of...
Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target
Immunocore Holdings plc (NASDAQ:IMCR) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 16, 2026, Jefferies downgraded Immunocore Holdings plc (NASDAQ:IMCR) to Hold from Buy previously with a price target of $33, down from $48, after assuming coverage. Jefferies has said that Immunocore Holdings plc’s (NASDAQ:IMCR) lead product […]
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress?
If you are trying to figure out whether Immunocore Holdings is attractively priced or already reflecting its potential, you are in the right place for a clear valuation breakdown. The share price closed at US$32.30 recently, with a 10.0% return over the past year but a 39.5% decline over three years and a 4.4% decline year to date, which may point to shifting views on both opportunity and risk. Recent news flow around Immunocore has focused on its pipeline progress and partnerships, which...